ETEsperanza Tuset

Esperanza Tuset

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esperanza Tuset has a total of 219 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition

    by Sara Torres-Esquius, Guillermo Ramil-López, Maria Gabarrós-Subirà, Marin Diaz-Beya, Eugènia Rivero, Lucia Garcia-Maño, Félix López-Cadenas, Concepción Fernandez-Rodriguez, Francesca Guijarro, Pamela Acha, et al.


  • 5′‐nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate‐risk cytogenetics

    by Johana Díaz‐Santa, Rocío Rodríguez‐Romanos, Rosa Coll, Gemma Osca, Marta Pratcorona, Marta González‐Bártulos, Ana Garrido, Anna Angona, Carme Talarn, Mar Tormo, et al.

    Acute myeloid leukemia (AML) is a complex disease, and its treatment needs to be adjusted to the risk, which is conferred by cytogenetics and molecular markers. Cytarabine is the main drug to treat AML, and it has been suggested that the genotype of cytarabine metabolizing enzymes may have a prognostic relevance in AML. Here we report the association between the 5′‐nucleotidase, cytosolic II (NT5C2) rs10883841, cytidine deaminase (CDA) rs2072671 and rs532545 genotypes and the clinical outcome of 477 intermediate‐risk cytogenetic AML patients receiving cytarabine‐based chemotherapy. Patients younger than 50 years old with the NT5C2 rs10883841 AA genotype had lower overall survival (OS) (p: .003; HR 2.16, 95% CI 1.29–3.61) and lower disease‐free survival (DFS) (p: .002; HR 2.45, 95% CI 1.41–4.27), associated to a higher relapse incidence (p: .010; HR 2.23, 95% CI 1.21–4.12). Interestingly, subgroup analysis showed that the negative effect of the NT5C2 rs10883841 AA genotype was detected in all subgroups except in patients with nucleophosmin mutation without high ratio FLT‐3 internal tandem duplication. CDA polymorphisms were associated with the complete remission rate after induction chemotherapy, without influencing OS. Further studies are warranted to determine whether this pharmacogenomic approach may be helpful to individualize AML treatment.

  • Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3

    by Jose Maria Raya, Taida Martín-Santos, Elisa Luño, Carmen Sanzo, Maria Luz Perez-Sirvent, Esperanza Such, José Tomás Navarro, Fuensanta Millá, Esther Alonso, Alicia Domingo, et al.

    To compare, from a biological and clinical perspective, a significant group of patients with AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) with another group of AML carrying different abnormalities of 3q at q21 or q26, the latter named as the AML abn(3q) group. We developed a national survey with the participation of 13 Spanish hospitals, and retrospectively reviewed (from 1990 to 2010) these subtypes of AML. Fifty-five patients were collected: 35 with AML inv(3)/t(3;3) and 20 with AML abn(3q). A data collecting page that included main features at diagnosis, therapeutic approach and response, and survival variables, was distributed and completed. We did not find significant differences in sex, age, history of myelodysplastic syndrome or chemo-/radiotherapy, clinical presentation, WBC and platelet counts, hemoglobin level, blasts immunophenotype, serum lactatedehydrogenase, peripheral blood and bone marrow cellular dysplasia, and bone marrow biopsy findings. Although the association with monosomy 7 was significantly more frequent in AML inv(3)/t(3;3), this did not seem to influence outcome. The lack of response to the different modalities of treatment and the aggressive course of the disease were the standard in both cohorts of patients. Although not yet recognized by the World Health Organization classification, our results are in agreement with the findings of other authors, who include both subsets of AML together in the same group of adverse prognosis. In an attempt to simplify and bound entities with similar genetic background and clinical behavior, it would be desirable to bring together both subgroups of AML in a single section.


  • Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1

    by María Rozman, José-Tomás Navarro, Leonor Arenillas, Anna Aventín, Teresa Giménez, Esther Alonso, Granada Perea, Mireia Camós, Mayda Navarrete, Esperanza Tuset, et al.

    Acute myeloid leukemia (AML) with myelodysplasia-related changes is characterized by the presence of multilineage dysplasia (MLD), frequently related to high-risk cytogenetics and poor outcome. However, the presence of MLD does not modify the favorable prognostic impact of NPM1 mutation. The prognosis of patients with AML presenting marked dysplasia lacking high-risk cytogenetics and NPM1 mutation is uncertain. We evaluated the prognostic impact of MLD in 177 patients with intermediate-risk cytogenetics AML (IR-AML) and wild-type NPM1. Patients were categorized as MLD-WHO (WHO myelodysplasia criteria; n = 43, 24 %), MLD-NRW (significant MLD non-reaching WHO criteria; n = 16, 9 %), absent MLD (n = 80, 45 %), or non-evaluable MLD (n = 38, 22 %). No differences concerning the main characteristics were observed between patients with or without MLD. Outcome of patients with MLD-WHO and MLD-NRW was similar, and significantly worse than patients lacking MLD. The presence of MLD (66 vs. 80 %, p = 0.03; HR, 95 % CI = 2.3, 1.08–4.08) and higher leukocyte count at diagnosis was the only variable associated with lower probability of complete remission after frontline therapy. Concerning survival, age and leukocytes showed an independent prognostic value, whereas MLD showed a trend to a negative impact (p = 0.087, HR, 95 % CI = 1.426, 0.95–2.142). Moreover, after excluding patients receiving an allogeneic stem cell transplantation in first CR, MLD was associated with a shorter survival (HR, 95 % CI = 1.599, 1.026–2.492; p = 0.038). In conclusion, MLD identifies a subgroup of patients with poorer outcome among patients with IR-AML and wild-type NPM1.


  • Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription

    by Arianne Pérez-García, Gemma Osca, Anna Bosch-Vizcaya, Nichollas Kelleher, Nazly Y. Santos, Rocío Rodríguez, Yolanda González, Josep M. Roncero, Rosa Coll, Maite Serrando, et al.


  • Open Access

    Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors

    by Anna Bosch-Vizcaya, Arianne Pérez-García, Salut Brunet, Carlos Solano, Ismael Buño, Vicent Guillem, Carolina Martínez-Laperche, Guillermo Sanz, Cristina Barrenetxea, Carmen Martínez, et al.


  • Linfocitosis B policlonal persistente: estudio de 35 casos

    by Lourdes Florensa, José Tomás Navarro, María Encarnación Pérez Vila, Alicia Domingo, Esmeralda De la Banda, Maria Rozman, Mireia Camós, Fuensanta Millá, Granada Perea, Esther Alonso, et al.


  • Genetic changes including gene copy number alterations and their relation to prognosis in childhood acute myeloid leukemia

    by Gemma Armengol, Anna Canellas, Yolanda Álvarez, Pilar Bastida, José Sánchez De Toledo, Maria del Mar Pérez-Iribarne, Mireia Camós, Esperanza Tuset, Jesús Estella, María Dolores Coll, et al.

    We studied a series of 68 subjects diagnosed with childhood acute myeloid leukemia (AML) using conventional cytogenetics and fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) to analyze mutations in FLT3 and NPM1 genes, and/or array comparative genomic hybridization (CGH). Cytogenetic/FISH abnormalities were observed in 71% of subjects, FLT3-ITD mutations in 15%, and NPM1 mutations in 13%. The array CGH alterations (average 3.6 per case) were observed in 96% of the tested subjects. The most frequent alterations were gains of 8q24.3 and 11p15.5-p15.4 in 16% of the samples. Six genes (AKT1, RUNX1, LTB, SDC1, RUNX1T1, and JAK2) from the imbalanced regions have been reported to be involved in AML, whereas other 30 cancer genes, not previously reported in an AML context, were identified as imbalanced. They probably correspond to non passenger alterations that cooperate with the recurrent translocations. The clinical data and genetic changes were tested to find out the possible association with prognosis. Genomic instability (four or more genomic imbalances) was correlated with poor patient outcome (p = 0.029).


  • Open Access

    Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status

    by Cinzia Lavarino, Idoia Garcia, Carlos Mackintosh, Nai-Kong V Cheung, Gema Domenech, José Ríos, Noelia Perez, Eva Rodríguez, Carmen de Torres, William L Gerald, et al.

    Background: Neuroblastic tumours (NBTs) represent a heterogeneous spectrum of neoplastic diseases associated with multiple genetic alterations. Structural and numerical chromosomal changes are frequent and are predictive parameters of NBTs outcome. We performed a comparative analysis of the biological entities constituted by NBTs with different ploidy status.Methods: Gene expression profiling of 49 diagnostic primary NBTs with ploidy data was performed using oligonucleotide microarray. Further analyses using Quantitative Real-Time Polymerase Chain Reaction (Q-PCR); array-Comparative Genomic Hybridization (aCGH); and Fluorescentin situHybridization (FISH) were performed to investigate the correlation between aneuploidy, chromosomal changes and gene expression profiles.Results: Gene expression profiling of 49 primary near-triploid and near-diploid/tetraploid NBTs revealed distinct expression profiles associated with each NBT subgroup. A statistically significant portion of genes mapped to 1p36 (P= 0.01) and 17p13-q21 (P< 0.0001), described as recurrently altered in NBTs. Over 90% of these genes showed higher expression in near-triploid NBTs and the majority are involved in cell differentiation pathways. Specific chromosomal abnormalities observed in NBTs, 1p loss, 17q and whole chromosome 17 gains, were reflected in the gene expression profiles. Comparison between gene copy number and expression levels suggests that differential expression might be only partly dependent on gene copy number. Intratumoural clonal heterogeneity was observed in all NBTs, with marked interclonal variability in near-diploid/tetraploid tumours.Conclusion: NBTs with different cellular DNA content display distinct transcriptional profiles with a significant portion of differentially expressed genes mapping to specific chromosomal regions known to be associated with outcome. Furthermore, our results demonstrate that these specific genetic abnormalities are highly heterogeneous in all NBTs, and suggest that NBTs with different ploidy status may result from different mechanisms of aneuploidy driving tumourigenesis.


  • Case Forum: Juvenile myelomonocytic leukemia

    by E. Tuset, I. Alcorta, S. Rives, T. Toll, J. Estella, M. Perez-Iribarne, C.M. Niemeyer